Q-omics provides the consensus-scored ZNF705E profile across patient tissues and cancer cell-line models. ZNF705E expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, ZNF705E is differentially expressed in 10, with the highest sampling consensus in KIRC. Additionally, ZNF705E RNA expression shows 17,858 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight HNSC, KIRC, and UVM as cancer lineages where ZNF705E shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZNF705E — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZNF705E survival associations across molecular data types. ZNF705E RNA expression shows survival associations in the most cancer types (23). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZNF705E RNA expression–survival associations across cancer types. High ZNF705E expression shows unfavorable associations in UVM and KICH, but favorable associations in HNSC, STAD, BLCA and GBM. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for ZNF705E RNA expression.
This table summarizes ZNF705E tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for ZNF705E. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZNF705E shows lower tumor expression in KICH and THCA and higher tumor expression in KIRC, LIHC, HNSC and LUAD. The KIRC box plot shows higher ZNF705E RNA expression in tumor versus normal tissue (log2 FC = +0.075, t-test p < 0.001).
This table shows molecular features associated with ZNF705E in patient tissues and cancer cell lines. In patient samples, ZNF705E shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, ZNF705E RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE.
